P0148 Beta-catenin as a prognostic marker in libyan patients with prostatic carcinoma

• Published in: European journal of cancer (1990) 2014-05, Vol.50, p.e51-e51
• Main Authors: Said, W, Emaetig, F, El Gehani, K, Eldarat, T, Buhmeida, A, Elzagheid, A, Al-Fituri, O
• Format: Article
• Language: English
• Subjects: Hematology, Oncology and Palliative Medicine
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/j.ejca.2014.03.192

Background At present, there are insufficient prognostic markers for prostate cancer. The aim of this study was to evaluate abnormalities of β -catenin protein expression and subcellular localisation and to determine its relation to different clinicopathological features and disease-free survival in prostate cancer patients. Methods β -Catenin was determined by immunohistochemistry in 40 prostate cancer specimens, obtained from patients with different stages of prostate cancer (83% stage IV) who underwent a radical prostatectomy or TURP between 2006 and 2011. The membranous expression was semiquantitatively. Clinical records of these patients were studied for follow-up data. Findings β -Catenin was over-expressed Libyan patients with prostate cancer. There was no statistically significant difference in β -catenin immunoexpression as regards histopathological type, perineural invasion, tumour stage, biological recurrence. However, β -catenin over-expression showed significant correlation with old age ( p < 0.024) and Gleason score ( p < 0.014). Conclusions Changes in expression and cell distribution of β -catenin correlate with the progression of prostate adenocarcinoma, signifying a role of this molecule as a marker of progression and prognosis. Further investigations, on a larger and more heterogeneous population, should be carried out to validate and extend our results.